✦ LIBER ✦

Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon α-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 or 24 weeks

✍ Scribed by Maribel Rodriguez-Torres; Sugantha Govindarajan; Moises Diago; Thomas Morgan; Bhupinderjit Anand; Karl Barange; Frank Suter; Amy Lin; Gregory Hooper; Mitchell Shiffman

Book ID: 111237995
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 194 KB
Volume: 29
Category: Article
ISSN: 0106-9543
DOI: 10.1111/j.1478-3231.2008.01859.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Peginterferon-α-2a (40KD) and Ribavirin

Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C

✍ Michael von Wagner; Miriam Huber; Thomas Berg; Holger Hinrichsen; Jens Rasenack; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 173 KB

Predictors of virologic relapse in patie

Predictors of virologic relapse in patients with chronic hepatitis C (CHC) treated with peginterferon alfa-2a (40KD) (pegasys) alone or in combination with ribavirin (copegus)

✍ V. Balan; S. Zeuzem; H. Sette; M. Fried; D. Jensen; G. Pastore; P. Marcellin; F. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 151 KB

328 Comparison of 48 or 72 weeks of trea

328 Comparison of 48 or 72 weeks of treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C infected with HCV genotype 1

✍ Thomas Berg; M. Von Wagner; H. Hinrichsen; T. Heintges; P. Buggisch; T. Goeser; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

734 Peginterferon alpha-2a (PEGASYS) plu

734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial

✍ M.L. Shiffman; S. Pappas; L. Nyberg; S. Greenbloom; A. Gibas; B. Bacons; J. Rase 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 124 KB

O.161 High SVR rates with 24 weeks of pe

O.161 High SVR rates with 24 weeks of peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 patients with a week-4 virological response

✍ P. Ferenci; T. Scherzer; H. Laferl; K. Staufer; A. Maieron; M. Gschwantler; H. B 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 140 KB

Treatment of patients with chronic hepat

Treatment of patients with chronic hepatitis C (CHC) with peginterferon alfa-2a (40KD) (Pegasys) alone or in combination with ribavirin (copegus) results in long-lasting sustained virological response

✍ M. Swain; M.-Y. Lai; M.L. Shiffman; W.G. Cooksley; A. Abergel; M. Diago; M. Brun 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 159 KB